Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

7.54USD
3:59pm EST
Change (% chg)

$0.24 (+3.29%)
Prev Close
$7.30
Open
$7.32
Day's High
$7.65
Day's Low
$7.17
Volume
1,409,354
Avg. Vol
1,624,707
52-wk High
$18.04
52-wk Low
$5.77

Latest Key Developments (Source: Significant Developments)

Glenview Capital Management reports 6.70 pct passive stake in Endo
Monday, 13 Nov 2017 04:41pm EST 

Nov 13 (Reuters) - Glenview Capital Management Llc::Glenview Capital Management Llc reports 6.70 percent passive stake in Endo International Plc as on October 31, 2017 - SEC filing‍​.  Full Article

Endo posts Q3 adjusted earnings per share $0.91
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Endo International Plc :Endo reports third-quarter 2017 financial results.Q3 adjusted earnings per share $0.91 from continuing operations.Q3 GAAP loss per share $0.45 from continuing operations.Q3 revenue $787 million versus I/B/E/S view $784.9 million.Q3 earnings per share view $0.71 -- Thomson Reuters I/B/E/S.Endo International - ‍for full twelve months ended december 31, 2017, at current exchange rates, Endo is reaffirming its full-year guidance on revenue​.Endo - ‍for full 12 months ended Dec 31, 2017, at current exchange rates, is reaffirming FY guidance on adjusted diluted EPS from continuing operations​.Endo International Plc - ‍during third-quarter 2017, company recorded pre-tax, non-cash asset impairment charges of $95 million​.Endo International Plc - sees FY ‍reported diluted GAAP loss per share from continuing operations to be between $4.94 and $4.64​.FY2017 earnings per share view $3.55, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo sees Q3 ‍revenues of about $785 million​
Monday, 30 Oct 2017 08:30am EDT 

Oct 30 (Reuters) - Endo International Plc :Endo announces certain preliminary financial results for third-quarter 2017 and affirms selected 2017 financial guidance.Sees FY 2017 revenue $3.38 billion to $3.53 billion.Q3 adjusted earnings per share $0.85 from continuing operations.Q3 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Endo International Plc - Sees Q3 ‍revenues of approximately $785 million​.Q3 revenue view $784.9 million -- Thomson Reuters I/B/E/S.FY2016 revenue view $3.92 billion -- Thomson Reuters I/B/E/S.Endo International Plc - ‍Expects 2017 adjusted EPS from continuing operations to be at upper end of guidance ranges of $3.35 to $3.65​.FY2017 earnings per share view $3.52, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.Endo International Plc - Qtrly ‍preliminary​ reported (GAAP) loss per share from continuing operations of about $0.45.Endo - ‍"Unaware" of any unapproved, non-sterile-to-sterile compounding facilities currently selling/distributing Vasopressin injection product​.  Full Article

Endo files federal lawsuit to obtain FDA compliance
Thursday, 26 Oct 2017 04:40pm EDT 

Oct 26 (Reuters) - Endo International Plc :Endo files federal lawsuit to obtain FDA compliance with drug quality and security act of 2013.Endo International - ‍lawsuit seeks immediate removal of vasopressin from FDA's Category 1 nominations list.Endo - Units filed suit in court against FDA seeking declaration that FDA's current framework allowing bulk compounding of numerous products is unlawful.Endo - seek removal of vasopressin from FDA's Category 1 nominations list to avoid bulk compounding of vasopressin ‍​by non-sterile-to-sterile outsourcing facilities‍​.  Full Article

Endo International completes divestiture of Grupo Farmacéutico SOMAR
Wednesday, 25 Oct 2017 04:30pm EDT 

Oct 25 (Reuters) - Endo International PLC :Endo completes divestiture of Grupo Farmacéutico SOMAR.  Full Article

Endo international begins shipment of generic Sabril for oral solution
Monday, 28 Aug 2017 07:30am EDT 

Aug 28 (Reuters) - Endo International Plc :Begins shipment of generic Sabril for oral solution.  Full Article

BRIEF-Endo International begins shipment of generic Sabril for oral solution
Monday, 28 Aug 2017 07:30am EDT 

Corrects to fix typo in headline:Begins shipment of generic Sabril for oral solution.  Full Article

Endo says continues to expect total generics segment to decline in the high single to low double digits pct range in 2017
Tuesday, 8 Aug 2017 08:20am EDT 

Aug 8 (Reuters) - Endo International Plc :Endo CEO says continues to expect total generics segment to decline in the high single to low double digits percentage range in 2017 - Conf Call.Endo CEO says now project full year sterile injectables revenues growth in the low to mid-20 percent range - Conf Call.Endo says expect overall branded revenue to decline in the mid to high teens percent range y-o-y based on continued generic competition and the withdrawal of Opana ER.Endo says expect 2017 international revenues to decline in the low 20s percentage range - Conf Call.  Full Article

Endo International reports Q2 GAAP loss per share $3.12 from continuing operations
Tuesday, 8 Aug 2017 06:30am EDT 

Aug 8 (Reuters) - Endo International Plc :Endo reports second-quarter 2017 financial results.Q2 adjusted earnings per share $0.93 from continuing operations.Q2 GAAP loss per share $3.12 from continuing operations.Q2 revenue $876 million versus i/b/e/s view $836.4 million.Q2 earnings per share view $0.73 -- Thomson Reuters I/B/E/S.Endo International Plc - ‍updates 2017 financial guidance​.Endo International Plc sees FY total revenues to be between $3.38 billion to $3.53 billion.Endo International Plc - ‍reports $725 million of impairment charges in quarter​.Endo International Plc sees FY adjusted diluted eps from continuing operations to be between $3.35 to $3.65.Endo International Plc sees FY adjusted ebitda from continuing operations to be between $1.48 billion to $1.56 billion.FY2017 earnings per share view $3.53, revenue view $3.49 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo announces agreements to resolve virtually all known U.S. mesh product liability claims
Monday, 7 Aug 2017 04:30pm EDT 

Aug 7 (Reuters) - Endo International Plc :Endo announces agreements to resolve virtually all known U.S. mesh product liability claims.‍under agreements, Endo will make installment payments beginning in Q4 of 2017 and continuing through Q4 of 2019​.‍As part of Q2 results, intends to increase mesh product liability accrual by $775 million, expected to cover about 22,000 U.S. mesh claims​.  Full Article

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.